Chardan Capital Increases Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $25.00
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its price objective increased by equities researchers at Chardan Capital from $23.00 to $25.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s target price indicates a potential upside of 227.23% from […]
More Stories
Home Depot (NYSE:HD) Upgraded at Stifel Nicolaus
Stifel Nicolaus upgraded shares of Home Depot (NYSE:HD – Free Report) from a hold rating to a buy rating in...
Deutsche Bank AG Acquires 15,258 Shares of Enerpac Tool Group Corp. (NYSE:EPAC)
Deutsche Bank AG raised its holdings in shares of Enerpac Tool Group Corp. (NYSE:EPAC – Free Report) by 45.8% during...
Janus Henderson Group PLC Has $888,000 Stock Position in GFL Environmental Inc. (NYSE:GFL)
Janus Henderson Group PLC reduced its holdings in shares of GFL Environmental Inc. (NYSE:GFL – Free Report) by 77.0% in...
CleanSpark, Inc. (NASDAQ:CLSK) Shares Acquired by Janus Henderson Group PLC
Janus Henderson Group PLC lifted its position in shares of CleanSpark, Inc. (NASDAQ:CLSK – Free Report) by 10.1% during the...
Focus Partners Wealth Takes Position in Uranium Energy Corp. (NYSEAMERICAN:UEC)
Focus Partners Wealth bought a new stake in Uranium Energy Corp. (NYSEAMERICAN:UEC – Free Report) during the 4th quarter, according...
A. O. Smith Co. (NYSE:AOS) Shares Sold by Janus Henderson Group PLC
Janus Henderson Group PLC cut its stake in shares of A. O. Smith Co. (NYSE:AOS – Free Report) by 7.3%...